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introduction: Though the human fetus is exposed to placentally derived human cho-
rionic gonadotropin (hCG) throughout gestation, the role of hCG on the fetal brain is 
unknown. Review of the available literature appears to indicate that groups of women 
with higher mean levels of hCG during pregnancy tend to have offspring with lower cere-
bral palsy (CP) risk. Given that newborn cerebral injury often precedes the development 
of CP, we aimed to determine whether hCG may protect against the neurodegenerative 
effects of neonatal brain injury.
Methods: We utilized the Rice–Vannucci model of neonatal cerebral hypoxia-ischemia 
(HI) in postnatal day 7 mice to examine whether intraperitoneal administration of hCG 
15–18 h prior, 1 h after or immediately following HI decrease brain tissue loss 7 days after 
injury. We next studied whether hCG has pro-survival and trophic properties in neurons 
by exposing immature cortical and hippocampal neurons to hCG in vitro and examining 
neurite sprouting and neuronal survival prior and after glutamate receptor-mediated 
excitotoxic injury.
results: We found that intraperitoneal injection of hCG 15 h prior to HI, but not at or 1 h 
after HI induction, resulted in a significant decrease in hippocampal and striatal tissue 
loss 7  days following brain injury. Furthermore, hCG reduced N-methyl-d-aspartate 
(NMDA)-mediated neuronal excitotoxicity in  vitro when neurons were continuously 
exposed to this hormone for 10 days or when given at the time and following neuronal 
injury. In addition, continuous in  vitro administration of hCG for 6–9  days increased 
neurite sprouting and basal neuronal survival as assessed by at least a 1-fold increase in 
MAP2 immunoreactivity and a 2.5-fold increase in NeuN + immunoreactivity.
conclusion: Our findings suggest that hCG can decrease HI-associated immature 
neural degeneration. The mechanism of action for this neuroprotective effect may partly 
involve inhibition of NMDA-dependent excitotoxic injury. This study supports the hypoth-
esis that hCG during pregnancy has the potential for protecting the developing brain 
against HI, an important CP risk factor.
Keywords: cerebral palsy, human chorionic gonadotropin, fetal brain, ischemia, neuroprotection, brain injury, 
excitotoxicity, chorionic gonadotropin
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inTrODUcTiOn
Human chorionic gonadotropin (hCG) is a placentally derived 
hormone produced by the syncytiotrophoblast following 
implantation. The human fetus is exposed to hCG throughout its 
intrauterine development (1). Back in early 1980s, hCG receptors 
(also known as lutropin receptors) were identified in multiple 
fetal organs such as kidney, lung, and colon (2, 3), thus suggest-
ing hCG’s role in fetal/neonatal growth and differentiation (4–7). 
However, little progress has been made over the years in defining 
this developmental role (4–7). Studies have shown that hCG 
can cross the blood–brain barrier, and that hCG receptors exist 
in fetal and neonatal rat brains (4–7). In vitro studies have also 
demonstrated that hCG decreases neuronal cell death, promotes 
the outgrowth of fetal neuronal cell processes, and supports the 
proliferation of neural stem cells (5, 8, 9). Furthermore, hCG can 
decrease ischemic brain injury in adult rodent models of stroke 
and it has been shown to improve functional recovery following 
spinal cord injury in rats (8, 10–14). Given the above evidence, 
hCG may act as neuroprotectant against the neurodegenerative 
effects of neonatal cerebral hypoxia-ischemia (HI).
Hypoxia-ischemia has been identified as a major cerebral 
palsy (CP) risk factor (15–18). Given that almost 90% of the 
CP-associated brain injuries occur in utero or around the time 
of birth (19, 20), if hCG does indeed protect against hypoxic-
ischemic brain injury, we would expect the offspring of women 
with increased levels of hCG to have a lower risk of CP. To explore 
this potential relationship, we searched the medical literature for 
studies pertaining to maternal hCG levels during pregnancies of 
singleton births and identified several distinct groups of women 
with decreased mean hCG levels during pregnancy. We then 
searched the literature for studies of CP risk for offspring born 
to each of these distinct groups. We found that that the groups of 
women with lower mean serum hCG tended to be at higher risk 
for having children with CP. For example, mean maternal hCG 
levels are significantly lower in women bearing boys, American 
women of Asian-descent, women bearing boys with cryptor-
chidism and women who are obese (compared with women 
bearing girls, American women of non-Asian descent, women 
bearing boys without cryptorchidism, and women of normal 
weight, respectively) (21–25). These same groups of women have 
increased CP risk for their offspring compared with their coun-
terparts (26–34). Thus, we indirectly identified a potential inverse 
hCG–CP relationship which provides support to the hypothesis 
that hCG has neuroprotective actions in the immature brain and 
may play a role in diminishing CP risk.
In the present work, we sought to directly examine whether 
hCG can serve as a neuroprotectant against the CP risk factor of 
neonatal HI. We first utilized the Rice–Vannucci model of mouse 
neonatal HI and investigated whether intraperitoneal (IP) hCG 
administration to postnatal day 7 (P7) mouse pups at three treat-
ment time points (15 h prior to hypoxia, 1 h prior to hypoxia and 
immediately after hypoxia) decreases cerebral tissue loss 7 days 
following injury. We then asked whether in vitro hCG exposure 
favors the survival and growth of immature neurons and protects 
them against N-methyl-d-aspartate (NMDA)-dependent excito-
toxic injury. To explore this second aim, dissociated immature 
hippocampal and/or cortical neurons were continuously exposed 
to hCG for one to up to 10 days, while we examined its effects 
on neuronal survival and neurite sprouting prior and after 
glutamate-mediated excitotoxic injury. Altogether, we found that 
peripheral pretreatment with hCG reduces the effects of neonatal 
cerebral HI in  vivo and that direct hCG exposure to neurons 
favors neuronal growth and survival under baseline and injuri-
ous conditions. The results described here support the hypothesis 
that hCG can act as a neuroprotectant in the developing brain. 
Future studies should aim at further exploration of the role of 
hCG in brain development as well as the mechanisms involved 
in hCG-mediated neuroprotection.
MaTerials anD MeThODs
animals and surgical Procedures
C57BL/6 (Charles River Laboratories Inc., Roanoke, IL, USA) 
mice were kept under 12/12 light/dark cycles with ad  libitum 
access to food and water. Neonatal hypoxic-ischemic brain 
injury was performed in male and female mouse pups at P7 as 
previously described (35). Only pups with a body weight greater 
than 3.0 g at the time of carotid surgery (P7) were used in this 
study. Briefly, pups were anesthetized using 3% halothane for 
induction and 2.5% halothane for maintenance (balance room 
air). Under anesthesia, blood flow through the left carotid artery 
was permanently interrupted by carotid artery cauterization 
through an incision in the neck. Following carotid surgery, pups 
were returned to the dam and allowed to recover for a minimum 
of 3 h. Pups were then placed in pairs into individual thermoregu-
lated hypoxia cylindrical chambers for 45 min at 36.5°C with 8% 
oxygen. Each chamber contained a control pup and hCG-treated 
pup. High-grade humidified 8% oxygen (±0.02%) balanced with 
nitrogen was used. After completion of the hypoxia period, pups 
were returned to the dam until the day they were euthanized at 
postnatal day 14 (P14). In order to avoid potential confounders 
related to changes in body temperature or other environmental 
conditions, for each experiment, the saline control and hCG-
treated animals were exposed at the same time to the hypoxia 
chamber and to the same temperature conditions and for the 
same duration of time. Similarly, every attempt was made to 
equalize the surgical and post-surgical recovery conditions of the 
control and hCG-treated groups.
hcg and Vehicle injections
For all in vivo and in vitro experiments described below (except 
as noted), the source of hCG was Sigma-Aldrich (St. Louis MO, 
USA, Catalog no. CG10). When noted that a different source of 
hCG was utilized, the source was Sigma-Aldrich (St. Louis MO, 
USA, Catalog no. C0434). Reconstitution of hormone powder was 
done in phosphate-buffered saline (PBS) as per manufacturer’s 
recommendations to a concentration of 10,000 IU/mL. Drug was 
then diluted to the specified concentrations in the corresponding 
control in vitro (control salt solution or neurobasal media) and 
in vivo (0.9% normal saline, NS) solutions.
A single 1,500 IU/kg IP injection of hCG was administered 
to pups exposed to 45 min of hypoxia after carotid ligation and 
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at three different time points: 15 h prior to hypoxia, 1 h prior to 
hypoxia, or immediately after hypoxia. NS-injected littermates 
were used as vehicle controls and exposed to the injury paradigm 
at the same time as the neonatal pups injected with hCG. Every 
attempt was made to segregate an equal number of males (M) 
and females (F) to each treatment group to account for gender-
based bias (total M/F; NS 18/14 and hCG 18/12). Drug or vehicle 
was injected into the IP space using a 30-G needle attached to 
a 100 μL Hamilton syringe (Hamilton, Reno, NV, USA). Given 
hCG’s long half-life of about 36 h (1, 36, 37), we chose to admin-
ister a single IP dose to minimize potential toxic additive effects 
of hCG. A dosage of 1,500 IU/kg of hCG was given since that is 
the dose that was shown to be effective and safe in adult murine 
stroke models (8).
histology and Tissue injury Quantification
At 7 days following HI, P14 mice pups were deeply anesthetized 
with pentobarbital (150  mg/kg) and perfused transcardially 
with ice-cold PBS containing 3  U/mL heparin. Brains were 
removed and immersion-fixed in 4% (w/v) paraformaldehyde 
(PFA) in 0.1 M phosphate buffer (pH 7.4) at 4°C for 24 h, and 
then cryoprotected in 30% (w/v) sucrose in 0.1  M phosphate 
buffer until freezing in powdered dry ice and sectioned into 
50 µm coronal sections with a freezing sliding microtome. The 
uninjured, contralateral right hemisphere was marked by nick-
ing it with a razor blade. A set of coronal brain sections (spaced 
50 µM apart) beginning at the genu of the corpus extending to 
the mid body of the dorsal hippocampus were mounted in DAPI 
mounting medium (Vector Labs) and imaged via Nanozoomer 
(Hamamatsu Photonics). Percentage of tissue loss was calculated 
by comparing the cortex, striatum, and hippocampus of the 
injured hemisphere (left) to the uninjured hemisphere (right) 
using the Nanozoomer imaging software as previously described 
(38, 39). Three coronal sections per quantification area per animal 
were used for each of the brain regions studied. Striatum volume 
was calculated using those sections containing the striatum at 
the level of the genu of the corpus callosum. Hippocampal injury 
was determined by analyzing sections containing all layers of the 
dorsal hippocampal formation. Cortical areas were analyzed on 
the sections that contained the dorsal hippocampus. The investi-
gators were blinded to the treatment during area analysis.
Determination of neonatal Mouse Body 
Temperature
Body temperature recordings were obtained by transiently 
introducing a miniature thermistor recording probe coated 
with triple antibiotic lubricating gel (TH-10Kmp thermistor, 
Cell MicroControls, Norfolk, VA, USA) into the rectum of a P7 
C57BL/6 mouse and connected to a 2 channel micro tempera-
ture controller (mTCII, Cell MicroControls, Norfolk, VA, USA). 
For the determination of body temperature during group hud-
dle (Figure 2A), a consistent five-mouse pup huddle was used. 
Animals were injected intraperitoneally with 0.9% NS-control 
solution or 1,500 IU/kg of hCG 1 h or 15–18 h prior to tempera-
ture recording. Recording of huddle pup temperature was done 
immediately and approximately within 20  s after the animal 
was taken out of the group huddle. For the recording of body 
temperature at a constant physiological temperature of 36.5°C 
and following removal from physiological to room temperature 
(Figures  2B–D), P7 pups treated with hCG (1,500 IU/kg) or 
0.9% NS vehicle 15–18 h prior to temperature recording were 
briefly anesthetized under halothane and the thermistor mini 
recording probe was introduced into the rectum. Subsequently, 
the probe was temporarily secured with adhesive tape to the 
proximal portion of the mouse tail. The pups were then allowed 
to fully recover from anesthesia for 30 min before any tempera-
ture recording. Anesthesia recovery and temperature equilibra-
tion were made in a thermoregulated hypoxia chamber set at 
a constant temperature of 36.5°C and supplied by a constant 
flow of humidified 21% FiO2 air. Following the 30-min post-
anesthesia period, the rectal temperature was recorded every 
minute for 10 min followed by the animal being removed from 
the thermoregulated 36.5°C chamber and into chamber set at 
a constant room ambient temperature of 23°C in 21% FIO2. In 
this chamber, the temperature was continuously recorded every 
minute for 30 min before the probe was removed. In order to 
minimize potential inter-recording variations among the con-
trol and hCG-treated groups, each single-temperature recording 
session was carried in parallel using a control, saline-treated, 
pup paired with an hCG-treated neonate. Every attempt was 
made to segregate an equal amount of males and females to each 
group (Control: 6 females/6 males; 1 h post-hCG: 3 females/2 
males; 15–18 h post-hCG: 6 females/6 males). Postnatal day 7 
mouse pups only weighing 3 g or more were included in these 
experiments and the average weight did not significantly differ 
among groups (Control: 3.5 ±  0.10  g, N =  12; 1  h post-hCG: 
3.4 ± 0.13 g, N = 5; 15–18 h hCG, 3.6 ± 0.14 g, N = 12).
Determination of serum hcg 
concentration
Serum was extracted from P7 pups via cardiac puncture 1  h 
or 15–18  h following IP hCG administration. Approximately 
50–70 µL of blood was obtained from each pup. Blood samples 
were immediately placed in serum separating cold microcen-
trifuge tubes and centrifuged at 10,000 rpm for 15 min. Serum 
samples were then loaded at 1:15 dilution into a 96-well com-
mercially available sandwich hCG enzyme-linked immunosorb-
ent assay (ELISA; ab100533, Abcam, Cambridge, MA, USA). 
Standard curve and serum samples were probed using the ELISA 
kit in duplicate and according to the manufacturer’s instructions. 
Conversion from ng/mL to IU/mL was determined using this 
assay and generating a second dilution curve from a known 
concentration of the hCG employed in the animal and cell experi-
ments (CG10, Sigma, St. Louis, MO, USA).
Dissociated cortical and hippocampal 
cultures and ibotenic acid-Mediated 
excitotoxic assay
The cortex and hippocampus were microdissected from 
embryonic day 18 C57BL/6 embryos and incubated in Hank’s 
balanced salt solution with 2.5% (10×) trypsin for 7  min at 
37°C. Following trypsin incubation, cells were dissociated into 
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a homogenous suspension by gentle pipetting tissue up and 
down 15–20 times utilizing a sterile 1mL pipette. The dissoci-
ated neurons of cortices and hippocampi were resuspended 
after cold centrifugation (4°C; 1,500 rpm) in neurobasal media 
and placed in 24-well plates precoated with Poly-l-Lysine. To 
avoid plating neurons at different densities in different wells, 
cells were plated at the same time from a common dissociated 
neuronal preparation at a calculated equal neuronal concentra-
tion of 100,000 cells/well; all neurons for a given experiment 
were plated simultaneously and treated equally prior to any 
drug or injury treatment. Although we did quantify the amount 
of neurons in each well, routine visual inspection of neurons 
under phase contrast microscopy prior to exposure to any form 
of treatment appeared to show consistent density, growth, and 
morphology across all wells. Cells were maintained in neuroba-
sal media plus 1X B-27 supplement, 0.5-mM l-glutamine with 
penicillin-streptomycin, and 50% of the media was replaced 
every 3–4  days. Neurons were examined in the presence or 
absence of hCG (diluted in neurobasal media at a concentra-
tion of 2 IU/mL unless otherwise specified). At DIV12, cultured 
neurons were washed with a controlled salt solution (CSS) 
containing 120-mM NaCl, 5.4-mM KCl, 1.2 mM CaCl2, 15-mM 
glucose, and 25-mM Tris–HCl, pH = 7.40, at room temperature. 
Magnesium was omitted to avoid blockade of the NMDA recep-
tor channels. Following the wash, cells were exposed to 50-µM 
Ibotenic acid (IBO) with 100-µM glycine in CSS or CSS alone 
for 5 min then washed and incubated in neurobasal media for 
24 h prior to lactase dehydrogenase (LDH) assay or cytological 
assessment as previously described (40).
lactate Dehydrogenase assay
At 24-h post-excitotoxic injury with IBO or prior to PFA fixa-
tion, media from individual wells of cortical and hippocampal 
neuron cultures were collected and assayed for LDH using a 
cytotoxicity detection kit (Roche) as previously described (38). 
Briefly, 100 µL of culture medium per well/sample in duplicate 
was incubated with gentle shaking with the kit reagents for 
30  min in the dark, after which the product was measured at 
490 nm utilizing a standard 96-well microplate reader (Bio-Tek 
Instruments). Following collection of conditioned media for 
LDH, cells were fixed with 4% PFA in phosphate buffer for 
30  min at room temperature. After washing with PBS, cells 
were permeabilized with PBS-X, blocked in normal serum, and 
probed for immunocytochemistry.
In Vitro immunofluorescence 
Quantification
Quantification of neurons and neuronal processes was achieved 
by staining PFA-fixed cortical and hippocampal neurons with 
a mouse MAP2 antibody (1:1,000, Millipore) or NeuN Alexa 
Fluor®488 conjugated antibody (1:100, Millipore). Sample digital 
images of MAP2 and NeuN stained neurons in control and 
hCG-treated neuronal cultures were obtained. For quantification, 
the analysis area (1 mm × 1 mm region) per digital image and 
the number of images and image characteristics (3–4 images/
neuronal culture well) in the culture well were the same for each 
experiment and treatment condition. Every attempt was made 
to select the same approximate location in the culture for each 
experimental condition in a treatment-blinded fashion. Areas 
were chosen away from the edge of the 1.6-cm culture and at 
approximately the 3, 6, 9, and 12 o’clock location. The amount 
of immunofluorescence was quantified utilizing ImageJ analysis 
software by thresholding the immunofluorescence of control 
conditions and automating the analysis of NeuN or MAP2 
immunofluorescence per region for all cultures while keeping the 
same threshold and image settings (41). Data were expressed as 
the average amount of immunofluorescence per fixed unit area. 
A single N-value represents average stain quantified per area per 
a single culture well.
chronic hcg exposure/iBO assay 
Procedure
Dissociated cortical and hippocampal late embryonic (E18) 
neurons were exposed to 2 IU/mL of hCG beginning at 3 days 
(DIV3) after plating and continuing until 24 h post-injury at 
DIV13 (totaling 10 days of hCG exposure). Excitotoxic injury 
was achieved by transient, 5-min, 50-µM IBO administration at 
DIV12 as previously described (40). An hCG concentration of 2 
IU/mL was first chosen given that this is the calculated average 
concentration of hCG present in human fetal amniotic fluid 
(42–44). Neuronal cell viability was measured by quantifying the 
amount of neurite degeneration via MAP2 staining 24 h post-
IBO administration and by examining lactate dehydrogenase 
activity (described above) in the culture media 24 h following 
injury.
acute hcg exposure/iBO assay 
Procedure
Dissociated E18 cortical neurons were allowed to grow for 12 days 
in the absence of hormone and then were transiently exposed to 
50-µM IBO for 5 min in the absence and presence of hCG at 
concentration of 2 and 20 IU/mL. Control neurons were exposed 
only to the control salt solution. hCG exposure continued for 24 
h after injury when the neurons were fixed in PFA and processed 
for MAP2 immunocytochemistry.
high-Dose hcg exposure
In a separate experiment and in order to evaluate the effects 
of high-dose hCG on neuronal cell count and neurite sprout-
ing, we continuously exposed neurons for 6 days to 2, 10, and 
100 IU/mL of hCG diluted in culture media starting at DIV3. 
After the hCG-exposure period, neurons were fixed in PFA and 
processed for MAP2, NeuN and GFAP immunocytochemistry.
statistics
Data are presented as mean ±  SEM and were compared using 
one-way ANOVA followed by Bonferroni test for multiple com-
parisons, one-sample t-test for hypothetical value comparisons, 
and one or two-tailed Student’s t-test for two-group comparisons 
unless otherwise specified. Statistical significance was set at 0.05 
where *p < 0.05 and **p < 0.01. Statistics were performed using 
GraphPad Prism (GraphPad software).
FigUre 1 | In vivo hCG IP administration protects the brain from the neurodegenerative effects of HI in a time-dependent manner. (a) The relative tissue losses 
[calculated by the percent difference between left (L) ipsilateral, ischemic, and right (R) contralateral, non-ischemic, hemisphere] in the hippocampus, striatum and 
cerebral cortex 7 days after carotid ligation followed by 45 min of hypoxia from NS-injected vs. hCG-injected (1,500 IU/kg) P7 mouse pups treated 15 h prior to HI. 
hCG treatment decreased hippocampal (NS 44.5 ± 3.9% vs. hCG 28.5 ± 3.8%) and striatal (NS 23.5 ± 3.1% vs. hCG 16.7 ± 2.3%) tissue loss following HI. Actual 
area values (average ± SEM mm2) in left vs. right hippocampus are 1.8 ± 0.12 vs. 0.97 ± 0.10 mm2 for NS and 1.8 ± 0.14 vs. 1.3 ± 0.10 mm2 for hCG. Average 
area values in left vs. right striatum are 3.3 ± 0.19 vs. 2.4 ± 0.12 mm2 for NS and 3.0 ± 0.16 vs. 2.5 ± 0.12 mm2 for hCG. (B) Representative coronal digital 
micrographs taken from injured NS- and hCG-injected animals treated 15 h prior to HI. Note the ex-vacuo dilatation of the left, ischemic, cerebral ventricle, and 
relative atrophy of the left hippocampal formation in the NS group compared with the contralateral brain. (c,D) IP injection of hCG (1,500 IU/kg) 1 h (c) or 
immediately after (D) neonatal injury in P7 neonatal pups did not protect against the neurodegenerative effects of HI. Error bars show SE; *p < 0.05 and **p < 0.01. 
hCG, human chorionic gonadotropin; HI, hypoxia-ischemia; Hipp, hippocampus; IP, intraperitoneal; NS, normal saline; Str, striatum.
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resUlTs
Pretreatment with hcg Protects the 
immature Brain from hypoxic-ischemic 
neonatal neurodegeneration
Term-equivalent C57BL/6 mouse pups were subjected to unilat-
eral carotid ligation followed by 45 min of 8% hypoxia. As shown 
in Figures  1A,B, IP administration of 1,500 IU/kg of hCG 15 
h prior to neonatal global cerebral hypoxia resulted in a 36% 
reduction in the amount of hippocampal tissue loss (% change 
in left vs. right brain; NS: 44.5 ± 3.9; hCG: 28.5 ± 3.8; p = 0.008) 
and a 29% reduction in striatal tissue loss (% change in left vs. 
right brain; NS: 23.5 ± 3.1; hCG: 16.7 ± 2.2; p = 0.049) 7 days 
after HI compared to saline-injected littermate controls. Next, 
1,500 IU/kg of hCG or saline control solution was injected into 
P7 pups either 1 h prior to hypoxia or immediately after hypoxia 
exposure. As shown in Figures 1C,D, IP administration of hCG 
given at these two time periods did not result in protection 
against cerebral degeneration following HI in any of the cerebral 
regions examined. We did not observe any deaths associated with 
hCG or saline injection and there were no significant changes in 
pup weight between control animals (4.10 ± 0.1 g; N = 32) and 
hCG-treated animals (4.08 ± 0.1 g; N = 30).
hcg exposure Does not affecting Body 
Temperature
Given that hCG receptors are implicated in the regulation of the 
central hypothalamic-pituitary-gonadal axis in adult rodents 
(11), and understanding that neonatal hypothermia has been 
shown to reduce cerebral tissue loss following HI (45), we 
asked whether the neuroprotective actions of peripheral hCG 
administration are attributed to a decrease in body temperature. 
Intraperitoneal injection of 1,500 IU/kg of hCG 1-h or 15–18-h 
post-hormone injection did not alter neonatal P7 pup tempera-
ture when temperature was obtained in mouse huddle conditions 
compared with saline-treated littermates (Figure  2A; saline 
control: 33.08 ± 0.34°C; 1 h post-hCG: 33.28 ± 0.18°C; 15–18 h 
post-hCG: 32.90 ± 0.42°C; N = 5/condition). Similarly, pup body 
FigUre 2 | IP administration of hCG (1,500 IU/kg) does not alter neonatal pup body temperature. (a,B) Body temperature as assessed by rectal temperature in 
neonatal P7 mouse pups did not change 1 h or 15–18 h following hCG injection when examined during pup huddling or during a constant physiological ambient 
temperature of 36.5°C. (c) Removal of individual neonatal P7 pups from physiological (36.5°C) to room temperature (23°C) produced a gradual decline in body 
temperature. hCG administration did not alter the rate of temperature decline upon ambient temperature exposure when examined 15–18 h after drug injection. 
Statistical comparisons were performed by repeated measures ANOVA followed by Bonferroni post hoc test. (D) Second-degree polynomial curve fit calculated 
from data in (c), demonstrating nearly identical temperature drops upon change in ambient temperature from 36.5 to 23°C in NS control and hCG-treated neonatal 
P7 pups. hCG, human chorionic gonadotropin; IP, intraperitoneal.
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temperature in mice exposed to a constant physiological ambi-
ent temperature of 36.5°C did differ between mice exposed to 
saline and those exposed to 1,500 IU/kg of hCG 15–18 h prior to 
temperature recording (Figure 2B; saline control: 36.7 ± 0.1°C; 
15–18 h post-hCG: 36.6 ± 0.1°C; N = 7/condition). Since neo-
natal mouse body temperature is highly dependent on ambient 
temperature (46, 47), we wanted to rule out the possibility of hCG 
altering the adaptation of the mouse neonate to rapid changes in 
ambient temperature. To examine this question, paired 15–18 h 
post-hCG- and saline-injected mouse pups were rapidly transi-
tioned from a 30-min period of constant physiological ambient 
temperature of 36.5°C to room ambient temperature (23°C) while 
body temperature was continuously recorded for 30 min. Under 
these conditions, pup temperature gradually declined to a nearly 
identical degree and pattern between hCG and saline-treated 
groups (Figures  2C,D). We did not examine hCG’s effect on 
brain temperature prior and following HI and thus, a confound-
ing effect of hCG on cerebral temperature in the injured neonate 
cannot be conclusively ruled out. Nevertheless, the presented 
data above suggest that hCG alone does not affect pup body 
temperature. Therefore, it is less likely that intrinsic differential 
effects of hCG on body temperature contribute significantly to 
the neuroprotective effect observed upon peripheral injection of 
hCG 15 h prior to HI.
Importantly and as shown in Figure  2C, the body tem-
perature of P7 pups is tightly dependent on ambient temperature. 
Therefore, transient secondary hypothermia can occur when 
animals are removed from the hypoxia chamber and placed back 
FigUre 3 | Serum hCG concentrations obtained from neonatal P7 mouse 
pups 1 and 15–18 h following IP 1,500 IU/kg hCG injection. Serum hCG 
levels (calculated in ng/mL) were obtained utilizing a commercially available 
hCG ELISA assay (ab100533, Abcam, Cambridge, MA, USA). Conversion to 
IU/mL was done using this assay and a known concentration of the hCG 
source employed in the animal and cell experiments (CG10, Sigma, St. Louis, 
MO, USA). No hCG IR was observed in control, NS-injected, mouse serum 
indicating no mouse protein cross-reactivity. The serum hCG concentration 
did not appear to differ significantly between 1 h (31.4 ± 3 ng/mL; 
0.41 ± 0.04 IU/mL) and 15–18 h (29.8 ± 4 ng/mL; 0.39 ± 0.06 IU/mL) 
post-IP hormone injection. These serum concentrations are similar to those 
found in human term amniotic fluid (43, 48). hCG, human chorionic 
gonadotropin; IP, intraperitoneal, IR, immunoreactivity; NS, normal saline.
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with the dam. In order to minimize this potential confounder, 
hCG- and saline-treated animals were exposed to the hypoxia-
chamber simultaneously and were placed back with the dam 
following hypoxia as a group while making every attempt to have 
an equal proportion of control and hCG-treated pups in each 
litter. Qualitatively, we did not observe differential treatment in 
the behavior of the mother toward either treatment condition 
with the dam resuming nesting and feeding of her pups almost 
immediately after being placed back in their cage.
serum hcg levels 1 and 15–18 h Post 
1,500 iU/kg hcg injection are similar  
to Those Found in the amniotic  
Fluid of Term human neonates
In order to have a better understanding of how the hCG dose 
used in this study relates to the serum levels commonly found in 
human cord blood and amniotic fluid, we extracted serum from 
the blood of P7 animals injected with 1,500 IU/kg of hCG 1 and 
15–18 h after hormone injection and determined their serum 
hCG levels (in ng/mL and IU/mL) utilizing a commercially 
available serum hCG ELISA assay. As shown in Figure  3, the 
mean ± SEM serum hCG concentrations in the 1 and 15–18 h 
post-hCG groups were 31.4 ± 3 and 29.8 ± 4 ng/mL, respectively. 
These levels corresponded to 0.41 ± 0.04 IU/mL (1 h post-hCG) 
and 0.39 ± 0.06 IU/mL (15–18 h post-hCG) when the internal 
standard curve of the ELISA assay was compared with a dilu-
tion curve generated by the hCG used in this study’s animal and 
in vitro experiments. Although the concentration of hCG in cord 
blood and amniotic fluid varies according to gestational age, 
prior studies report cord blood and amniotic fluid hCG levels in 
term neonates to be around 0.2 and 0.4 IU/mL, respectively, with 
amniotic fluid levels averaging about 2 IU/mL during the third 
trimester of pregnancy (43, 48). Taken together, the above serum 
hCG levels found following a single-IP hCG dose of 1,500 IU/mL 
appear to be within the range observed in humans.
chronic In Vitro exposure of immature 
cortical and hippocampal neurons to hcg 
Protects against nMDa-Dependent 
excitotoxic injury
We then investigated whether chronic (10-day) exposure of 
immature neurons to 2 IU/mL hCG, a concentration of hormone 
found in human amniotic fluid (42–44), protects against NMDA-
mediated excitotoxic neurodegeneration. Chronic hCG exposure 
resulted in a significant decrease in neuronal NMDA-mediated 
excitotoxicity; this is demonstrated by the relative increase in 
the percent of MAP2 immunoreactivity (IR) in hippocampal 
(0.79 ± 0.3 vs. 25.5 ± 8.4%; p = 0.021) and cortical (11.74 ± 4.4 
vs. 77.1 ±  8.8%; p =  0.001) neuronal cultures 24 h following 
excitotoxic insult with IBO (Figures  4A–C) as compared with 
non-hCG exposed neurons. Similarly, hippocampal and cortical 
cultures chronically exposed to hCG demonstrated a significant 
decrease in the percent elevation of LDH activity in the culture 
media 24 h following IBO exposure (92.6 ± 4.8 vs. 58.3 ± 9.4%; 
p = 0.015; and 88.4 ± 5.4 vs. 53.3 ± 6.2%; p = 0.001, respectively; 
Figure 4C). The combination of these findings (increased neurite 
preservation and decreased LDH activity) suggests that prolonged 
exposure (beginning before injury) of hCG (2 IU/mL) directly 
to immature dissociated brain neurons is capable of decreasing 
NMDA-mediated excitotoxic neurodegeneration.
acute In Vitro hcg exposure Protects 
neurons against nMDa-Mediated 
excitotoxic neurodegeneration
We then investigated whether acute exposure of immature 
neurons to low-dose hCG (2 IU/mL) or to high-dose hCG (20 
IU/mL) protects against NMDA-mediated excitotoxic neurode-
generation. hCG administered at the time and 24 h following IBO 
exposure significantly reduced IBO-mediated cortical neurite 
neurodegeneration by 55% (p < 0.01) at 2 IU/mL hCG and by 46% 
(p < 0.05) at 20 IU/mL hCG when compared with their respective 
non-hCG-treated injured neuronal controls (Figures 5A–E). The 
neuroprotection seen at 2 IU/mL hCG concentration vs. that seen 
at 20 IU/mL hCG concentrations was not significantly different 
from each other (Figure 5E). These data indicate that hCG, when 
administered directly to neurons at the time of injury is able to 
reduce NMDA-mediated neuronal excitotoxicity.
early (DiV3) high-Dose hcg exposure 
In Vitro increases Basal neuronal survival
We also studied the potential neurotrophic effects of hCG by 
examining basal neuronal survival of immature cortical neurons 
FigUre 4 | In vitro chronic, 10-day, hCG exposure to immature cortical and hippocampal neurons is not toxic and protects them from NMDA-dependent 
excitotoxic injury. (a,B) MAP2 fluorescence following immunocytochemical staining of dissociated cortical and hippocampal neurons exposed to control vs. 2 IU/mL 
of hCG for 9 days prior and 24 h following IBO (50 µM; IBO) exposure. Prolonged hCG did not appear to affect neuronal survival. Note also the relative preservation 
of neurites in hCG-exposed neurons after IBO exposure (most noticeable in cortical neurons) compared with control (CSS; controlled salt solution). (c) Quantitative 
bar graph analysis of the effects of hCG on neuronal survival as a measure of LDH activity in the neuronal media or MAP2 IR in control and hCG-treated neuronal 
cultures 24 h after injury with IBO. Cortical and hippocampal neurons exposed to hCG demonstrated a reduction in IBO-mediated increases in LDH activity and a 
relative preservation of neurite staining compared with non-hCG-treated cells. Scale bars = 165 µm. Error bars show SE; *p < 0.05 and **p < 0.01. hCG, human 
chorionic gonadotropin; IBO, ibotenic acid; IR, immunoreactivity; LDH, lactase dehydrogenase.
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exposed to high concentrations of hCG starting at DIV3. Six-
day hCG treatment at 100 IU/mL concentration resulted in a 
visible (Figure 6A) and quantitative (Figure 6B) 1.05 ± 0.2-fold 
(p  =  0.034) increase in neurite sprouting as seen in MAP2 
immunofluorescence staining and a quantitative 2.5 ± 0.5-fold 
(p =  0.038) increase in neuronal cell count as seen in NeuN 
immunofluorescence staining.
Neuronal MAP2 +  cell processes in high-dose hCG-treated 
neurons appeared longer and more complex suggesting the 
possibility of an hCG-mediated increased in neurite sprouting 
(Figure  6A). Interestingly, we also observed daily progressive 
grouping of neurons surrounded by morphologically appearing 
astrocytes only in the cultures exposed to high 100 IU/mL hCG. 
Triple staining of these cultures with MAP2, NeuN, and GFAP 
confirmed the increased presence of GFAP + astrocytes 6 days 
following high-dose hCG exposure. In contrast, GFAP + staining 
was almost completely absent in non-hCG-treated neurons at this 
time in culture (Figure 6A). Similarly, in a separate experiment 
utilizing a different source of hCG, we observed a significant 
1.3 ± 0.36-fold (p = 0.002; N = 3; graph not shown) increase in 
MAP2-IR following continuous 9-day hCG administration at a 
concentration of 500 ng/mL. Taken together, these data support 
the conclusion that prolonged, direct exposure of neurons to high 
hCG concentrations under basal conditions promotes neuronal 
survival and potentially increases neuronal sprouting.
DiscUssiOn
The in  vivo study results suggest that hCG decreases HI brain 
injury when the neonate is exposed to hCG before the hypoxic-
ischemic event occurs. When hCG was peripherally administered 
many hours (≥15 h) before HI induction, its effect against neo-
natal hippocampal and striatal injury was clearly evident. Since 
the human fetus is chronically exposed to placentally derived 
hCG throughout its intrauterine life, hCG may potentially play 
a physiological role in protecting the developing brain from 
hypoxic-ischemic events that occur in utero or around the time 
of birth.
In order to examine the in  vivo neuroprotective actions of 
hCG, we chose the Rice–Vannucci model of neonatal HI for this 
FigUre 5 | Acute neuronal hCG exposure in vitro protects neurons against NMDA-mediated excitotoxic neurodegeneration. (a) Representative low-power digital 
micrograph of MAP2 IR in DIV12 cultured, non-injured/non-hCG-treated, cortical neurons. (B–D) Representative digital micrographs of DIV12 cultured MAP2-
stained neuronal fibers 24 h following exposure to the NMDA-receptor agonist, IBO in the presence or absence of 2 or 20 IU/mL of hCG when hCG is administered 
during and following IBO exposure. (e) Quantitative summary of the neuroprotective effect of acute hCG administration 24 h post-IBO administration. Percent 
neurite degeneration was obtained as a function of the percent change in MAP2-IR from non-IBO control neurons. Scale bar = 220 µm. N = 4/condition.  
Error bars show SE; *p < 0.05 and **p < 0.01. hCG, human chorionic gonadotropin; IBO, ibotenic acid; IR, immunoreactivity.
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study because this model has been widely used by researchers 
to examine perinatal hypoxic-ischemic brain injury (49–51). 
This model is unique in that its combination of unilateral 
carotid occlusion and the systemic hypoxia produces the type 
of hypoxic-ischemic brain injury in limbic (hippocampus) 
and basal ganglia (striatum) regions that can be observed in 
moderately to severely affected human neonates. However, this 
injury model is only a functional model of neonatal injury and 
a limitation of this paradigm is that it does not truly simulate 
the exact environmental and physiological parameters that are 
seen in newborn HI. Furthermore, the degree of injury used in 
our model does not induce robust tissue loss in the cortex (35). 
This is also a limitation of the employed injury paradigm because 
hypoxic-ischemic events in the human fetus/newborn do often 
include the cerebral cortex (52). Perhaps the relatively small 
amount (approximately 5%) (35) of cortical tissue loss after HI 
FigUre 6 | Early (DIV3) high-dose hCG (100 IU/mL) exposure in vitro increases neuronal cell count and neurite sprouting. (a) Representative low-power 
micrographs of DIV9 cortical neurons exposed to high-dose (10 and 100 IU/mL) hCG for 6 days and triple-stained with the neurite marker, MAP2, the neuron-
specific marker, NeuN, and the astrocyte-specific marker, GFAP. Prolonged high concentrations of hCG resulted in large grouping of neurons with more complex 
neurite processes surrounded by GFAP + astrocytes. In contrast, GFAP + astrocytes are nearly absent in non-hCG-treated cultures at DIV9. Small rectangular 
inserts demonstrate a morphologically appearing GFAP + astrocyte (arrow) nearby a small group of NeuN + neurons. (B) A significant increase in MAP2 IR and 
visible increases in neuronal sprouting were observed with greater than 2 IU/mL concentrations of hCG. High-dose hCG (100 IU/mL) appeared to qualitatively and 
quantitatively increased NeuN + IR. Scale bar = 80 µm. N = 3/condition. Error bars show SE; *p < 0.05 and **p < 0.01. hCG, human chorionic gonadotropin; IR, 
immunoreactivity.
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induction observed explains the apparent lack of protection by 
hCG against the cortical injury seen in this study.
Because hypothermia is known to reduce cerebral injury 
after HI (45, 53) and central hCG receptors are known to affect 
hypothalamic function (11) (a brain region importantly involved 
in core body temperature regulation), we examined whether 
hCG’s neuroprotective actions are attributed to a decrease in 
body temperature. We confirmed the previous observation (54) 
demonstrating that the body temperature of P7 neonates is highly 
dependent on ambient temperature with rapid decreases in pup 
temperature observed upon transfer of the neonates from 37 to 
23°C; this effect has the potential to cause unwanted hypothermia 
and alter the degree of cerebral injury. Importantly, we found that 
IP administration of hCG does not affect the body temperature 
of healthy P7 neonates. Nevertheless, we did not examine 
body temperature prior and after hCG injection in the injured 
newborn mouse. Neonatal HI has been shown to decrease body 
temperature in rodents (55). Therefore, we cannot rule out the 
possibility that in the setting of HI, hCG potentiates a further 
drop in body temperature which, in turn, could contribute to the 
observed decrease in cerebral tissue loss. The potential contribu-
tion of hCG to mouse temperature during and after brain injury 
should be explored in future studies in order to better understand 
the neuroprotective effect of hCG found in this report.
Regarding the neonatal age examined, though induction of 
HI sooner after birth (such as on postnatal 5) may have altered 
the degree of cortical injury, we chose to follow a more com-
mon protocol for this model which involves induction of HI 
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at P7. Of note, this age in a mouse most closely approximates 
the developmental stage of late preterm human infants. Future 
studies can examine brain injury at postnatal days before and 
after this time point to assess whether hCG has differential 
neuroprotective properties depending on the stage of brain 
development. In this study, we also evaluated the brains of mouse 
pups at 7 day post-injury. Since brain injury may potentially still 
be evolving at this time, future studies should also examine the 
long-term effects of hCG-mediated protection to affirm that the 
neuroprotection is permanent. The reason that we also tested 
hCG after HI induction was to determine whether there may be a 
potential benefit for hCG administration to an infant postnatally 
if an HI event occurs shortly after birth. However, our results 
do not suggest that this is the case since we did not see any 
reduction in brain injury when hCG was administered shortly 
before or immediately after the induction of HI. Therefore, our 
findings suggest that the neurological effects of hCG may only be 
protective and not reparative. Perhaps once neurodegenerative 
cellular processes have already been triggered, hCG exposure is 
ineffective. It is also possible that hCG may offer beneficial effects 
against HI-mediated cerebral injury that were not detected by 
the hCG dose examined by our outcome measure (i.e., percent-
age of region-specific tissue loss). An alternative explanation of 
the apparent lack of effect when administered right before or 
after injury may be related to the mode of hCG administration. 
Available human and animal data indicate that peak blood levels 
of hCG are not achieved until at least 3 h following intramuscular 
administration (which is known to be a faster route of delivery 
to that of the IP route) (36, 56–59). Therefore, pharmacologically 
relevant hCG actions on the brain may not begin until hours 
after IP administration. hCG treatment immediately post HI or 
1 h prior to neonatal injury may thus not accurately reflect the 
full protective or potential restorative actions of this hormone in 
the injured brain.
The difficulty over the years in defining a possible physiologic 
role of hCG in human fetal development has been partially 
attributed to a lack of suitable animal models. In humans, both 
(placentally derived) hCG and (pituitary-derived) luteinizing 
hormone (LH) bind to the same lutropin receptor (LHR) (1, 44). 
Despite some biological and functional differences between these 
hormones, hCG is highly analogous to LH and is often regarded 
as a super powerful form of it. Lutropin receptors have been 
identified in almost all species ranging from rodents to human 
(60, 61). However, the presence of two different LHR ligands (LH 
and hCG) is primarily a human phenomenon; most mammals 
(except for humans, primates and horses) produce only LH 
(44). Given that rodents do not naturally produce any type of 
chorionic gonadotropin, rodent models are not relevant models 
in distinguishing physiologic vs. pharmacologic levels of hCG; 
unlike human fetuses/neonates, no dosage of hCG is physiologi-
cal to a neonatal rodent. That said, we find that the 1,500 IU/kg 
dose of hCG administered intraperitoneally in this study is a 
close approximation to the hCG levels seen in human amniotic 
fluid at term (43). We justify the use of the rodent model in this 
study as a way to determine a possible neuroprotective role for 
hCG in fetal development and not to establish the dosage that 
would be required to achieve the effect.
In the second part of the study, we directly explored the actions 
of hCG on neuronal degeneration following in  vitro neuronal 
injury. The pathologic process of excitotoxicity occurs when 
glutamate receptors, such as NMDA receptors, are overactivated; 
excessive NMDA receptor stimulation is known to result in neu-
ronal damage or death via rapid increases in intracellular calcium 
(17, 62, 63). NMDA-mediated excitotoxicity plays a pathophysi-
ological role in a wide range of other brain-injury paradigms 
such as following focal or global cerebral ischemia (17, 63, 64). In 
particular, glutamate-dependent excitotoxicity is a contributor 
to the pro-degenerative mechanisms involved in neonatal HI 
(63, 64). For example, HI-mediated brain injury in term-equiv-
alent neonatal rats can be significantly reduced by pre-treatment 
with the NMDA antagonist, MK801 (65, 66). Conversely, 
overactivation of neuronal NMDA receptors in vitro by NMDA, 
or in  vitro and in  vivo by the NMDA-agonist, IBO, results in 
dose-dependent cerebral and neuronal degeneration (40, 67).
Given the above, we utilized the well-characterized model 
of in vitro NMDA-mediated neuronal excitotoxicity to examine 
whether hCG inhibits excitotoxic neuronal degeneration of 
immature cortical and hippocampal neurons. In this model, 
inhibition of excitotoxic neuronal degeneration is measured by 
a decrease in LDH activity accompanied by a decrease in per-
centage of injury-triggered neurite loss. Importantly, our study 
shows that hCG protected neurons against glutamate-mediated 
excitotoxicity after prolonged hCG exposure as well as follow-
ing acute drug exposure at the time of injury. Furthermore, our 
results suggest that hCG likely blocks NMDA-mediated damage 
to cell bodies as well as to neuronal processes, since degenerating 
neurites do not release LDH (68). Therefore, acute and prolonged 
in  vitro hCG exposure protects neuronal cell bodies and their 
processes from the degenerative effects of NMDA-receptor 
overactivation. It is important to note, however, that cerebral 
injury mediated via glutamate receptor activation is only a partial 
contributor in the pathogenesis of cerebral HI and other cellular 
mechanisms may contribute to the neuroprotective actions of 
hCG as discussed below.
Remarkably, the amount of basal neuron and neurite density 
increased when cortical cultures were exposed to hCG con-
centrations higher than 2 IU/mL. This result is consistent with 
previous observations which indicate a dose-dependent increase 
in the number of neurite-bearing dissociated rat brain neurons 
following 3-day hCG exposure (6). Importantly, hCG contains 
domains encountered in the protein family of neurotrophic gly-
coproteins (69). Thus, the observed hCG-dependent increases in 
MAP2-stained fiber density may be indicative of hCG’s potential 
neurotrophic actions on immature neurons. It will be important 
in future studies to determine (a) which signaling pathways are 
activated in the brain by hCG, (b) which receptors are required for 
neuroprotective effects, and (c) whether neuroprotective effects 
are due to cell autonomous vs. non-cell autonomous mechanisms.
All in all, the results of this study enhance our understand-
ing of the potential physiologic role of hCG in neuroprotection 
during brain development. The findings described in this report 
suggest that hCG is capable of decreasing the injury of immature 
neurons in  vivo (prophylactically) and in  vitro. In addition, 
our findings show that peripheral hCG exposure prior to HI is 
12
Movsas et al. hCG and Neonatal Cerebral Hypoxia-Ischemia
Frontiers in Pediatrics | www.frontiersin.org November 2017 | Volume 5 | Article 232
required to decrease neuronal injury. This raises the possibility 
that preterm infants, at higher than normal risk for HI-simulated 
events postnatally, may benefit from prophylactic administration 
of hCG. After all, preterm infants are prematurely deprived of 
placental hCG exposure due to their early separation from pla-
centally derived hormones. In other words, the developing brains 
of preterm infants would naturally have had longer exposure to 
hCG had they remained in utero until term. Future preclinical 
studies should be performed to further evaluate whether hCG 
supplementation to preterm infants at physiologically appropri-
ate levels (to compensate for hCG deprivation) is beneficial. Of 
important note, administration of hCG at 1,500 IU/kg results in 
serum concentrations that have the potential to alter the levels 
of other hormones such as testosterone. Thus, further preclinical 
and clinical studies will be needed to determine whether there 
is an hCG dose that is effective at providing neuroprotection to 
injured neonates while producing minimal potentially adverse 
systemic effects if it is to be considered for clinical use.
Our results also suggest that one of hCG’s mechanisms of 
neuroprotection may be related to its inhibition of NMDA-
dependent excitotoxic neurodegeneration. Yet, it is important to 
emphasize that hCG has multiple cellular targets in peripheral 
tissues and brain (11, 44). Therefore, the neuroprotective actions 
of hCG may be multifactorial and thus, it is unlikely that hCG’s 
ability to reduce glutamate-mediated excitotoxic injury is its 
only mechanism of action. For example, hCG may further 
ameliorate the effects of cerebral injury in preterm and term 
newborns by dampening systemic and/or central inflammation. 
Emerging research in human reproduction demonstrates that 
one of hCG’s important roles in pregnancy is to modulate the 
maternal immune response and prevent the rejection and demise 
of the semi-allogenic fetus (70). hCG modulates the phagocytic 
action of macrophages, dampens the pro-inflammatory activ-
ity of T-lymphocytes, inhibits B-cell antibody production and 
suppresses the synthesis of pro-inflammatory cytokines such as 
TNF-α and interferon-gamma (71–77). hCG also increases the 
synthesis of anti-inflammatory cytokines such as IL-10 (76), as 
well as activates the production of pro-survival immunomodu-
latory cytokines such as leukemia inhibitory factor (78–82). 
Interestingly, all the above hCG-regulated proteins play a very 
important role in the pathogenesis of cerebral white matter 
degeneration of the newborn, a condition that significantly con-
tributes to the development of CP in term and preterm neonates 
(83). Therefore, future studies should be performed to better 
characterize the systemic and central-nervous-system-mediated 
mechanisms that may contribute to the potentially beneficial 
effects of this hormone against the effects of early cerebral injury.
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